Loading organizations...

§ Venture Capital · Seoul, South Korea
Smart Korea UTC Bio-Healthcare Venture Fund operates as a dedicated venture capital entity, channeling investment into the burgeoning bio-healthcare sector. Its core function involves identifying and financing innovative biotech companies, applying a strategic approach to capital deployment both within South Korea and across international markets. The fund specializes in providing more than just financial backing, extending tailored growth support programs to its portfolio companies, thereby fostering their development and market penetration.
The fund was established with UTC Investment serving as its managing entity, becoming active around 2021. This initiative was born from the insight that significant opportunities existed in providing specialized capital and operational guidance to biotech ventures. UTC Investment leverages its expertise to navigate the complex landscape of healthcare innovation, positioning the fund to support advancements in medical and biological technologies.
The fund’s beneficiaries are emerging biotech companies engaged in developing pioneering solutions and products within the healthcare domain. Its vision is to cultivate a robust ecosystem for bio-healthcare innovation by empowering these firms with the necessary resources to scale their operations and bring transformative technologies to fruition, ultimately contributing to global health progress.
Smart Korea UTC Bio-Healthcare Venture Fund has 1 tracked investment across 1 company. The latest tracked deal is $26.2M Grant / Series B in PDC*line Pharma in December 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 6, 2021 | PDC*line Pharma | $26.2M Grant / Series B | Sangwoo LEE | Alpha Holdings, Brain Asset Management, Hansongneotech, Noshaq, Sambrinvest, Fontaine François, Sriw, Walloon Region |